Trial Profile
Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Acoustic neuroma; Neurofibromatosis 2
- Focus Therapeutic Use
- 03 Aug 2023 Results published in the Neuro-Oncology
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 22 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Sep 2020.